IM vs SubQ injections for hormones: what the evidence actually shows

What's this video probably claiming?

Based on the caption and hashtag context, this video appears to be breaking down the practical differences between intramuscular (IM) and subcutaneous (SubQ) injection methods, likely in the context of testosterone replacement therapy (TRT) and possibly peptide administration. The creator is probably arguing that IM injections offer faster absorption and more stable blood levels, while SubQ is gentler and more accessible for self-administration. Given the hashtags include testosteroneforwomen and hormonehealth, there's a good chance the video is positioning SubQ as a viable and underutilized option for women on hormone protocols. The framing looks educational, aimed at patients who are already in or considering a monitored protocol. That's fine, as far as it goes. But the devil is in the details, and some of those details have been significantly complicated by recent pharmacokinetic research.

What does the science actually show?

The traditional teaching, IM is faster and SubQ is slower, turns out to be more nuanced than most wellness content acknowledges. A 2017 pharmacokinetic study by Spratt et al. published in the Journal of Clinical Endocrinology and Metabolism found that subcutaneous testosterone injections produced comparable bioavailability to IM, with testosterone cypionate reaching similar peak concentrations via both routes. The real differences show up in peak timing and trough variability. IM injections of testosterone cypionate typically peak within 24 to 72 hours and trough around day 7 to 14, depending on dose. SubQ injections tend to produce a slightly flatter, more extended release curve. A 2021 study by Flores et al. in Andrology found that SubQ testosterone produced lower peak-to-trough ratios in transgender men, which some clinicians prefer precisely because it reduces the symptom swings associated with IM peaks. Neither route is categorically superior. They produce different curves, and the right choice depends on the patient's protocol, goals, and tolerability.

Where does the social media noise diverge from clinical reality?

The biggest problem with TikTok content on injection routes is the tendency to flatten clinical nuance into a ranking system. Creators often imply SubQ is the smarter, modern choice while IM is old-fashioned, or vice versa. That's not how endocrinologists are actually making these decisions. The Spratt 2017 data and subsequent work by Kaminetsky et al. (2011, Journal of Sexual Medicine) make clear that route selection should hinge on individual pharmacokinetic response, injection site tolerability, and whether the prescribing clinician is monitoring labs at appropriate intervals. Another red flag in this content category is the blending of peptide and hormone administration advice. Peptides like BPC-157 or CJC-1295 have entirely different pharmacokinetic profiles than testosterone, and applying the same IM versus SubQ logic across both categories is not supported by strong human clinical trial data. Most peptide injection research is preclinical or anecdotal, and that distinction rarely gets made clearly in short-form video content.

What should you actually know?

If you are on a supervised hormone protocol and your provider has specified an injection route, there is almost certainly a reason grounded in your labs, your dosing schedule, and your response history. Switching routes without clinical oversight is not a harmless experiment. SubQ testosterone, for instance, can produce higher dihydrotestosterone (DHT) conversion in some patients due to higher 5-alpha reductase activity in adipose tissue, a finding noted in the Spratt 2017 analysis. For women on low-dose testosterone, this matters. On the peptide side, the situation is even more unsettled. Most peptides discussed in this content category lack strong human pharmacokinetic data comparing injection routes at all. The legitimate clinical question of IM versus SubQ is a reasonable one. However, the answer requires individualized medical judgment, not a TikTok ranking. If a video is encouraging you to switch injection methods or combine hormone and peptide protocols based on general principles, that's a prompt to talk to your prescriber, not a protocol update.